716 related articles for article (PubMed ID: 12600227)
1. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice.
Altamura AC; Sassella F; Santini A; Montresor C; Fumagalli S; Mundo E
Drugs; 2003; 63(5):493-512. PubMed ID: 12600227
[TBL] [Abstract][Full Text] [Related]
2. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
3. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M; Osman E
Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
[TBL] [Abstract][Full Text] [Related]
4. Depot perphenazine decanoate and enanthate for schizophrenia.
David A; Quraishi S; Rathbone J
Cochrane Database Syst Rev; 2005 Jul; 2005(3):CD001717. PubMed ID: 16034865
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetics of long-acting antipsychotic medications.
Spanarello S; La Ferla T
Curr Clin Pharmacol; 2014; 9(3):310-7. PubMed ID: 23343447
[TBL] [Abstract][Full Text] [Related]
6. Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis.
Ostuzzi G; Bertolini F; Del Giovane C; Tedeschi F; Bovo C; Gastaldon C; Nosé M; Ogheri F; Papola D; Purgato M; Turrini G; Correll CU; Barbui C
Am J Psychiatry; 2021 May; 178(5):424-436. PubMed ID: 33596679
[TBL] [Abstract][Full Text] [Related]
7. Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives.
Möller HJ
Drugs; 2007; 67(11):1541-66. PubMed ID: 17661527
[TBL] [Abstract][Full Text] [Related]
8. Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia.
Park EJ; Amatya S; Kim MS; Park JH; Seol E; Lee H; Shin YH; Na DH
Arch Pharm Res; 2013 Jun; 36(6):651-9. PubMed ID: 23543652
[TBL] [Abstract][Full Text] [Related]
9. Depot perphenazine decanoate and enanthate for schizophrenia.
Quraishi S; David A
Cochrane Database Syst Rev; 2000; (2):CD001717. PubMed ID: 10796445
[TBL] [Abstract][Full Text] [Related]
10. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics.
Turner M; Eerdekens E; Jacko M; Eerdekens M
Int Clin Psychopharmacol; 2004 Jul; 19(4):241-9. PubMed ID: 15201572
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.
Kirson NY; Weiden PJ; Yermakov S; Huang W; Samuelson T; Offord SJ; Greenberg PE; Wong BJ
J Clin Psychiatry; 2013 Jun; 74(6):568-75. PubMed ID: 23842008
[TBL] [Abstract][Full Text] [Related]
12. Depot pipothiazine palmitate and undecylenate for schizophrenia.
Quraishi S; David A
Cochrane Database Syst Rev; 2001; (3):CD001720. PubMed ID: 11686995
[TBL] [Abstract][Full Text] [Related]
13. Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses.
Coutinho E; Fenton M; Quraishi S
Cochrane Database Syst Rev; 2000; 1999(2):CD001164. PubMed ID: 10796607
[TBL] [Abstract][Full Text] [Related]
14. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
Citrome L; Jaffe A; Levine J
Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
[TBL] [Abstract][Full Text] [Related]
15. Olanzapine: a review of rapid and long-acting parenteral formulations.
Owen RT
Drugs Today (Barc); 2010 Mar; 46(3):173-81. PubMed ID: 20467591
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics of the depot antipsychotics.
Jann MW; Ereshefsky L; Saklad SR
Clin Pharmacokinet; 1985; 10(4):315-33. PubMed ID: 2864156
[TBL] [Abstract][Full Text] [Related]
17. Long-acting injectable antipsychotics and the development of postinjection delirium/sedation syndrome (PDSS).
Novakovic V; Adel T; Peselow E; Lindenmayer JP
Clin Neuropharmacol; 2013; 36(2):59-62. PubMed ID: 23503549
[TBL] [Abstract][Full Text] [Related]
18. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.
De Graeve D; Smet A; Mehnert A; Caleo S; Miadi-Fargier H; Mosqueda GJ; Lecompte D; Peuskens J
Pharmacoeconomics; 2005; 23 Suppl 1():35-47. PubMed ID: 16416760
[TBL] [Abstract][Full Text] [Related]
19. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
[TBL] [Abstract][Full Text] [Related]
20. Spotlight on ziprasidone in schizophrenia and schizoaffective disorder.
Gunasekara NS; Spencer CM; Keating GM
CNS Drugs; 2002; 16(9):645-52. PubMed ID: 12153335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
